Camber Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,500,000
| Closed | -$65.3M | – | 45 |
|
|
2023
Q3 | $65.3M | Sell |
1,500,000
-300,000
| -17% | -$13.1M | 2.15% | 18 |
|
|
2023
Q2 | $65M | Buy |
1,800,000
+400,000
| +29% | +$14.5M | 2.12% | 17 |
|
|
2023
Q1 | $52.1M | Hold |
1,400,000
| – | – | 1.6% | 17 |
|
|
2022
Q4 | $63.4M | Sell |
1,400,000
-600,000
| -30% | -$27.2M | 2.18% | 17 |
|
|
2022
Q3 | $140M | Buy |
2,000,000
+1,350,000
| +208% | +$94.3M | 4.28% | 7 |
|
|
2022
Q2 | $43.6M | Sell |
650,000
-550,000
| -46% | -$36.9M | 1.89% | 19 |
|
|
2022
Q1 | $98.7M | Buy |
1,200,000
+625,000
| +109% | +$51.4M | 3.57% | 14 |
|
|
2021
Q4 | $84.3M | Buy |
575,000
+125,000
| +28% | +$18.3M | 2.9% | 13 |
|
|
2021
Q3 | $79.6M | Buy |
450,000
+50,000
| +13% | +$8.85M | 2.45% | 17 |
|
|
2021
Q2 | $64.6M | Buy |
400,000
+275,000
| +220% | +$44.4M | 2.18% | 19 |
|
|
2021
Q1 | $21.4M | Buy |
+125,000
| New | +$21.4M | 0.73% | 29 |
|